Patents Assigned to HINOVA PHARMACEUTICALS INC.
-
Patent number: 11926618Abstract: A compound of formula (I) or an optical isomer thereof, and pharmaceutically acceptable salts, prodrugs, aquo-complexes or non-aqueous-solvent complexes thereof are provided. Experiments prove that, compared with a control compound MGL-3196, the compound of formula (I), which is obtained through specific substitution sites and specific substitution types, is higher in agonist activity to THR-beta and significantly improved in selectivity on THR-beta/THR-alpha. The compound can be used in preparing THR-beta agonist and drugs for treating adaption diseases (including dyslipidemia, hypercholesteremia, non-alcoholic steatohepatitis and non-alcoholic fatty liver disease) applicable to the THR-beta agonist.Type: GrantFiled: August 20, 2020Date of Patent: March 12, 2024Assignee: HINOVA PHARMACEUTICALS INC.Inventors: Wu Du, Yu Li, Haibo Li, Yuanwei Chen, Chengzhi Zhang, Xinghai Li
-
Patent number: 11891379Abstract: This disclosure provides a compound as shown in formula (I) or optical isomers, pharmaceutically acceptable salts, hydrates or solvates thereof. In formula (I), R1-R18 are independently selected from hydrogen and deuterium respectively, but not all are hydrogen at the same time. The compound and salts, hydrates or solvates thereof can be used as FAK inhibitors, and used in the preparation of anti-cancer drugs, and compared with the undeuterated control compound Defactinib, the compound has significantly improved metabolic stability and pharmacokinetic properties.Type: GrantFiled: May 6, 2019Date of Patent: February 6, 2024Assignee: HINOVA PHARMACEUTICALS INC.Inventors: Wu Du, Yu Li, Kun Wen, Xinghai Li, Yuanwei Chen
-
Patent number: 11753392Abstract: A novel method for synthesizing deuterated amides and deuterated sulfonamides includes the following steps: (1) adding a compound M, DMAP, R3—X to a solvent to obtain a compound N after a reaction is complete; and (2) adding the compound N, R4—NH—R5, or a salt and base thereof to a solvent, and purifying after a reaction is complete to obtain a compound I.Type: GrantFiled: April 12, 2019Date of Patent: September 12, 2023Assignee: HINOVA PHARMACEUTICALS INC.Inventors: Wu Du, Kun Wen, Jinyun He, Haibo Li, Dekun Qin, Xinghai Li, Yuanwei Chen
-
Patent number: 11591301Abstract: A compound is represented by formula (I). A pharmaceutical composition contains the compound of formula (I). The compound is used in the preparation of an indoleamine-2,3-dioxygenase (IDO) inhibitor drug. The compound exhibits inhibition effect on IDO protease and metabolizes stably in the body. The compound or pharmaceutical composition thereof can be used for preparing an IDO inhibitor drug, and can also be used for preparing a drug for preventing and/or treating diseases having IDO-mediated tryptophan metabolic pathway pathological features.Type: GrantFiled: January 31, 2019Date of Patent: February 28, 2023Assignee: HINOVA PHARMACEUTICALS INC.Inventors: Wu Du, Wen Ren, Haibin Lv, Haibo Li, Kun Wen, Jinyun He, Dekun Qin, Xinghai Li, Yuanwei Chen
-
Patent number: 11572371Abstract: Disclosed is a BRD4 inhibitor as shown in formula I, belonging to the field of compound drugs. The compound provided has a good inhibitory effect on prostate cancer cell proliferation, and can be used for preparing a drug combatting tumors, autoimmune or inflammatory diseases and viral infection, and in particular an anti-prostate cancer drug.Type: GrantFiled: September 14, 2018Date of Patent: February 7, 2023Assignee: HINOVA PHARMACEUTICALS INC.Inventors: Lei Fan, Kexin Xu, Ke Chen, Fei Wang, Xiaoquan Wu, Tongchuan Luo, Shaohua Zhang, Xinghai Li, Yuanwei Chen
-
Patent number: 11447477Abstract: Provided is a compound represented by formula (I). Also provided are a pharmaceutical composition containing the compound of formula (I) and use of the compound in preparing indoleamine-2,3-dioxygenase (IDO) inhibitor drugs. The compound or the pharmaceutical composition thereof can be used for preparing drugs for preventing and/or treating diseases having pathological features of IDO-mediated tryptophan metabolic pathways.Type: GrantFiled: December 20, 2018Date of Patent: September 20, 2022Assignee: HINOVA PHARMACEUTICALS INC.Inventors: Wu Du, Chaowu Ai, Yu Li, Kun Wen, Haibin Lv, Wen Ren, Jinyun He, Dekun Qin, Xinghai Li, Yuanwei Chen
-
Patent number: 10450274Abstract: Quinoline compounds and salts, hydrates or solvates serving as a selective uric acid reabsorption inhibitor, can be used in the treatment of hyperuricemia and gout by promoting uric acid to excrete from the body and reducing serum uric acid. Such compounds have the effect of reducing the uric acid in the animal body and human body.Type: GrantFiled: December 6, 2016Date of Patent: October 22, 2019Assignee: HINOVA PHARMACEUTICALS INC.Inventors: Lei Fan, Wu Du, Xinghai Li, Yuanwei Chen, Kexin Xu, Ke Chen, Shaohua Zhang, Tongchuan Luo
-
Patent number: 9708289Abstract: Provided are imidazolidinedione compounds of formula (I), processes for preparation, uses and pharmaceutically compositions thereof. Said imidazolidinedione compounds possess androgen receptor antagonist activity and can be used for preventing and treating diseases and disorders related to androgen receptor, such as prostate cancer, alopecia, hair regeneration, acne and adolescent acne.Type: GrantFiled: May 27, 2014Date of Patent: July 18, 2017Assignee: Hinova Pharmaceuticals Inc.Inventors: Yuanwei Chen, Yu Gong
-
Publication number: 20160152592Abstract: Provided are imidazolidinedione compounds of formula (I), processes for preparation, uses and pharmaceutically compositions thereof. Said imidazolidinedione compounds possess androgen receptor antagonist activity and can be used for preventing and treating diseases and disorders related to androgen receptor, such as prostate cancer, alopecia, hair regeneration, acne and adolescent acne.Type: ApplicationFiled: May 27, 2014Publication date: June 2, 2016Applicant: HINOVA PHARMACEUTICALS INC.Inventors: Yuanwei CHEN, Yu GONG
-
Patent number: 9346764Abstract: Provided are imidazolidinedione compounds of formula (I), processes for preparation, uses and pharmaceutically compositions thereof. The imidazolidinedione compounds posses androgen receptor antagonist activity and can be used for preventing and treating diseases and disorders related to androgen receptor, such as prostate cancer, alopecia, hair regeneration, acne and adolescent acne.Type: GrantFiled: December 13, 2012Date of Patent: May 24, 2016Assignee: HINOVA PHARMACEUTICALS INC.Inventor: Yuanwei Chen